Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), EVP Joseph Truitt sold 50,000 shares of Achillion Pharmaceuticals stock on the open market in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $6.02, for a total value of $301,000.00. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), weekly performance is 169.04%. On last trading day company shares ended up $7.29. Analysts mean target price for the company is $5.44. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), distance from 50-day simple moving average (SMA50) is 144.65%.
Inovio Pharmaceuticals Inc (NYSEMKT:INO), recently announced that the company has initiated its phase I/IIA clinical-trial to evaluate the safety, immunogenicity & clinical responses of INO-3112,- the immunotherapy product, in the treatment of human papillomavirus- associated head & neck cancer. Inovio Pharmaceuticals Inc (NYSEMKT:INO), fell 5.57% in last trading session and ended the day on $8.82. INO, return on assets is -71.90%. Inovio Pharmaceuticals Inc (NYSEMKT:INO), quarterly performance is -37.18%.
Enzon Pharmaceuticals Inc (NASDAQ:ENZN)’s shares dropped 10.17% to $1.06. The company on May 1 announced that its Board of Directors (the “Board”) has adopted a stockholder rights plan (the “Rights Plan”) in an effort to preserve the value of its net operating loss carryforwards (“NOLs”) under Section 382 of the Internal Revenue Code. Enzon’s use of its NOLs could be substantially limited if the Company experiences an “ownership change” (as defined in Section 382 of the Internal Revenue Code). Enzon Pharmaceuticals Inc (NASDAQ:ENZN), shares moved down 8.47% in last trading session and was closed at $1.08, while trading in range of $1.03 – 1.15. Enzon Pharmaceuticals Inc (NASDAQ:ENZN),year to date (YTD) performance is -6.90%.
Shares of Oncothyreon Inc (USA) (NASDAQ:ONTY), jumped up 3.4% after the company declared that it has moved into a partnership deal with Celldex Therapeutics, Inc., (CLDX). Both the firms would join hands on a joint clinical trial of ONT-10 and varlilumab (CDX-1127). The phase Ib trial would be an open label study, wherein ONT-10 will be administered at the recommended single agent dose in combination with varlilumab at two dose levels in patients suffering from advanced breast or ovarian cancer.Oncothyreon Inc (USA) (NASDAQ:ONTY), ended the last trading day at $3.26. Company weekly volatility is calculated as 6.36% and price to cash ratio as 3.63. Oncothyreon Inc (USA) (NASDAQ:ONTY), showed a positive weekly performance of 3.36%.
Advaxis, Inc. (NASDAQ:ADXS)‘s stock had its “outperform” rating restated by Zacks in a research report issued on Tuesday. They currently have a $10.00 price objective on the stock. Zacks‘s target price points to a potential upside of 189.86% from the stock’s previous close. Advaxis, Inc. (NASDAQ:ADXS), weekly performance is 0.31%. On last trading day company shares ended up $3.26. Analysts mean target price for the company is $14.00. Advaxis, Inc. (NASDAQ:ADXS), distance from 50-day simple moving average (SMA50) is 15.15%.